From Singapore and Australia to India.

Cordlife now a part of your Life

Total Stem Cell

Banking Solution
Lifetime protection for your baby & family

QR SH 8.1.a 1
 What are stem cells ?
Stem cells are body’s master/mother cells as they
can differentiate into different types of cells to form
organ systems of the body.

There are four accessible sources namely:

• Bone marrow
• Peripheral blood
• Umbilical cord blood (UCB)
• Umbilical cord tissue(Msc, EpSC)

UCB SC have a number of clear advantages over

other stem cells:
• Reduced Ageing (Naïve)
• Immunological Naivety- minimal GvHD
• Ease of collection (safe, painless)

UCB can only be collected at the point of birth

One chance One Choice
QR 8.1.1-1-8 2
 Umbilical Cord Stem Cells (UCSCs)
Cord Blood consists of – • Hematopoietic stem cells (HSCs)
• Mesenchymal stem cells (MSCs)
• Unidentified stem cells (USCs)
Cord Tissues consists of – • Mesenchymal stem cells (MSCs)
• Epithelial stem cells (EpSCs)
UCSCs have shown immense potential to treat diseases and repair
injured tissues or organs
► Heart aliments / attack ► Cerebral Palsy
► Stroke ► Leukaemia
► Cartilage ► Breast Cancer
► Healing of wounds especially that of diabetic ulcers
MSCs can also be used with cord blood stem cells to increase the
success rate of cord blood transplants
Today, > 80 diseases officially recognised as treatable
diseases with cord blood stem cells, increasing each year

AABB QR8.1.1.12_DCR198
 Why choose Cordlife for
umbilical cord stem cells banking?
ØThe Only private Stem Cell bank in the world to
have patented technology to isolate both
mesenchymal stem cells (MSCs) epithelial
stem cells (EpSCs)
ØAll other banks can isolate only MSCs

CORDLIFE
CORDLIFE

More MSCs isolated Two cells lines

than other banks isolated
AABB QR8.1.1.12_DCR198
 Technology that has been used in actual
treatment – importance of EpSCs
AABB QR8.1.1.12_DCR198
 Severe wounds from accidents,
Gives tissues (flesh & Skins) growth
AABB QR8.1.1.12_DCR198
 Diabetic sores , prevent patient’s
limb-parts amputation
AABB QR8.1.1.12_DCR198
 Cerebral Palsy
(movement disorder)
“Our son Dallas was
diagnosed at 8 months with
cerebral palsy, a type of brain
injury from birth that has no
known cure
cure.. (He) was among
the first in the [U
[U..S.] to be
infused with his own cord
blood stem cells
cells.. Today, … he
runs, he laughs and he's
beginning to talktalk..”

– Derak and Cynthia

Hextell, founders of the
Dallas Hextell Foundation
(www.dallashextellfoundation.org)
.
CordLife released a Client’s cord blood unit for Therapy in
a child with Cerebral Palsy

Child was 2 ½ year old Georgia, who was

diagnosed with Cerebral Palsy after birth.
Her parents had chosen Cordlife and banked
her cord blood with Cordlife at birth. A chance
of live saving with stem cell therapy –
Cordlife, One Chance One Choice
Brain Repair
Type 1 Diabetes
¨ 20
20--30 new child cases each year
¨ Trials in University of Florida
¤Improved blood sugar control
¤In certain cases, no longer need insulin injections
Cord Blood Transplant first for adult cancer patient
Monday, 8 July, 2002, UK

A leukaemia sufferer has become the first adult in the UK to undergo a bone marrow transplant using blood
from a baby's umbilical cord.
Stephen Knox, 31, underwent the treatment - previously only performed on children - after being given just
months to live.
The procedure was developed by Professor Stephen Proctor, who used stem cell blood from discarded placentas
and umbilical cords.
Prof Proctor, based at Newcastle Hospital Trust's Haematology Unit and at Newcastle University, said Mr Knox
had responded well to the transplant.
It's a really exciting development and opens up huge possibilities

Professor Stephen Proctor

The operation was carried out on Mr Knox, of Middleton-St-George, near Darlington, after various
chemotherapy sessions failed to stem the leukaemia.
Mr Knox was given treatment to kill off his own bone marrow and then injected with the mixed cord blood that
has grown into new bone marrow.
Mr Knox is in remission in hospital after undergoing the procedure in February.
Mr Proctor said: "This treatment was his only hope.
"Stephen is progressing much better than we thought he would and the transplant has worked much better and
more quickly than we expected.
AABB QR8.1.1.12_DCR198
AABB QR8.1.1.12_DCR198
 India's FIRST successful Stem Cell Therapy for Spinal Cord Injury
A press meet Jointly by Life Line Hospital & NCRM

Mr. Akbar Ali in the press meet (In the centre with blue tops and pyjama)
flanked by (From L.R) Dr JS Rajkumar (Chairman Life Line Hospital),
Dr Narayanan (Neurosurgeon), Dr Ravikumar (Stem Cell Project Coordinator)
Dr Baskaran (CEO, Life Line) Mr Yuji Okada (Consul, Consulate of Japan, Chennai),
Dr Samuel JK Abraham (NCRM)
Source: National Geographic, July 2005

Picture on the left shows the spinal cord
compression (Yellow arrows) and
vertebral bone damage (Red Arrows).
Picture on the right was taken after the
bones were fixed in a surgery using plates
and screws.
A few points of scientific importance
About the cell source and their
mechanism:
In any such injury the damage is caused
to the neural component and vascular
component. The time within which the
anatomical correction is undertaken
(surgical fixing of the bones in this case)
and adjunct therapies are started are very
important. Earlier the treatment is given
better could be the outcome.
About the cell source and their
mechanism:
1. The cells used were NOT from any other
source such as embryo or Umbilical cord
blood or another human donor, but from
his own bone marrow. Therefore this is
safe.
2. The cells were not contaminated with
any other biological material from human
or animal origin.
3. The bone marrow stem cells do the
repair in two ways: (i) Majority of the cells
secrete trophic factors which help repair
neural and vascular damages (ii) a small
portion of the cells undergo fusion-
differentiation to become nerve cells.
 Manipal Hospital discovers cure for Parkinson`s disease (Apr. 04th., 2007)

Mr Andrew Kisana, a 58-year-old patient affected by Parkinson’s disease has

shown positive signs of cure with stem cell therapy.
With the success in treating this patient, India-based Manipal Hospital has proved
that stem cell therapy could be a potential option for easing out symptoms in a
patient suffering from Parkinson’s disease.
Parkinson’s disease is a neuro-degenerative disease that affects people over the
age of 50.

Source:http://stemcell.taragana.net/archive/success-rate-of-stem-cell-therapy-in-india-is-encouraging/
18
Stem Cell Therapy: The Holy Grail of Medicine
Stem cell therapy is the new buzz in medical corridors with 'miracle' cures being
reported everyday. Nancy Singh analyses the promises it holds for various
diseases and the growing market for it.
Stem cell therapy is said to be expensive, however, considering that the effects of
treatment are long lasting, without requiring expensive repetitive treatment, this
seems affordable. Frost & Sullivan estimates that the annual cost of $2,500 per
patient for SCT, at the manufacturer's level, is an average cost distributed over
several years.
For large scale of production of stem cell lines, consistency is the key factor. Dr Mahendra Rao
of Stem Cell Biology Unit, Gerontology Research Center, US, agrees, "Researchers must be
able to repeat each other's experiments and establish a baseline set of quality controls that will
be required for large scale therapy."

Four-month-old Aarohi Bhatt recently created medical history for being cured of a
rare heart condition believed to be untreatable. The cause of her cure—Stem Cell
Therapy (SCT) using her own blood at Frontier Lifeline Hospital, Chennai. Besides
being a difficult surgery, it was for the first time in the world that SCT was
successfully done on a child so young.
 Number of Diseases Treatable
with Cord Blood Stem Cells is Increasing
Year 2000 & before 2002 – 2004 2006-Present

No. of cord blood Over 1,000 Over 2,500 Over 10,000

therapies (reported in 2000) (Reported in Nov 2003) (reported in Jun 2008)

No. of diseases treatable 46 74 82 recognised

107 including ongoing
clinical trials

Cordlife group technology and A sample used in therapy

as reported by international news & medical journals

Nature Biotechnology – A Global

The Straits Times, July
1st2004. Authoritative Medical Journal
Ryan Foo; 3 years old.
Diagnosed with acute lymphoblastic leukemia (ALL) treated with younger sister’s
sample stored with CordLife.
18 months later: Leukemia in remission and Ryan has since started school.
QR 8.1.1-1-8 20
 List of Applications for Stem Cell
Transplantation and Therapy

Today, > 80 diseases treatable

with cord blood stem cells, increasing
each year
Malignant Diseases (Cancers)
Leukaemia
Neuroblastoma
(Cancer of the nervous system)
Lymphoma
(Cancer of the lymph glands)
Osteosarcoma (Bone Cancer)
Wilms’ Tumour (Kidney Cancer)
Breast Cancer

Non-Malignant Diseases Clinical Trials

Fanconi’s Anaemia Brain Tumour
Bubble Boy Disease (SCID) Ovarian Cancer
Sickle Cell Anaemia Lung Cancer
Aplastic Anaemia Type 1 Diabetes
Thalassaemia (Major) Cerebral Palsy
Krabbe Disease

QR 8.1.1-1-8 21
 Factors important to the success of a
therapy
• Human Leukocyte Antigen (HLA) matching between donor and
recipient

• Post-therapy care to minimize chances of secondary infection

• Dose of stem cells received

– ↑cell dose, ↑therapy success / survival *
Cell dose = number of nucleated cells per kg of body weight • X – Ray Wavier A Must
• Close proximity to facility
• Secured collection kit

Every Cell Counts, Every degree of temperature & Every Minute - viability decreases

Cell Dose* Is The Single Most Important Factor.

According To International Medical Standards, At Least 15 Million Cells Per Kg Is Required Before Any
therapy Is Attempted.

QR 8.1.1-1-8 22
 Technology are internationally
patented in various countries
including India and Europe.
This technology is used only
by Cordlife

AABB QR8.1.1.12_DCR198
AABB QR8.1.1.12_DCR198
 Profile of Cord
CordLife India is a subsidiary of the Cordlife Group
The First Foreign owned and operated stem cell bank in India
CordLife group is a Public listed company on the mainboard of the Australian
Securities Exchange (www.asx.com.au Ticker code CBB)
• Has the most number of stem cell banking facilities in the world today
since 2001
• The group has no franchises/“technical collaboration” or distributors
Same promoter /owner from Singapore to Australia now in India
• All facilities are designed; built & operated by technical teams from
Singapore & Australia. Facility managed by Medical Doctor

AABB QR8.1.1.12_DCR198
 Secured Facility –
Designed for the future, serving you
today
• Designed to customised requirements by Technical teams from
Singapore, United States and Australia
• Storage set up with multiple fail-safe systems ,
• Fire-retardant walls
• 365 days backup system, 24-hour emergency
• power supply
• Connected to back-up power generator
• Can remain at optimal Temperature
for over 2 weeks with no power required India
• Storage facility can hold up to 30,000 scalable
up to a few lac units
• Controlled access to the laboratory

Make an appointment to view our state-of-the-art

laboratory!
QR 8.1.1-1-8 Singapore Hong Kong
26
 Cordlife international therapy
track record
• Release of Cord Blood to over102 patients* from inception
• Till date units released have been used to treat over 18 indications at over
28 institutions globally*
• Increasing number of units released as cord blood applications increase
40
Genetic
35
Blood Disease
30 Cancers 9%
25 85%
20

15

10 Cell
5 Therapy
0 6%
2000 2001 2002 2003 2004 2005 2006 2007 2008
*Data derived from CordLife Group
and Associates
*Data derived from CordLife and
Partners International Facilities

QR 8.1.1-1-8 27
 Cordlife international therapy network
With 10 years of experience, Cordlife is the only trusted
international bank able to coordinate therapies at renowned
centres in India and globally:
Therapy Centre City Location
AIIMS New Delhi India
Apollo Speciality Hospital Chennai India
Chan Gung Children Hospital Taipei Taiwan
Dana Farber Cancer Centre Boston USA We know how: who: where: to receive
Dharmais National Cancer Centre Jakarta Indonesia best quality stem cell therapies
Duke University Medical Centre Durham USA
Erasmus Medical Centre Rotterdam Netherlands
Fred Hutchinson Cancer Centre Seattle USA
Hospital Saint Louis Paris France
Institute Gustave Roussy Villejuif France
Kanagawa Cancer Centre Japan Kanagawa
Karolinska University Hospital Stockholm Sweden
KK Women and Children's Hospital Singapore Singapore
Massachusetts General Hospital Boston USA
MD Anderson Medical Centre Houston USA
Mount Elizabeth Hospital Singapore Singapore
Mt Sinai Medical Centre New York USA
National Taiwan Hospital Taipei Taiwan
Queen Mary Hong Kong Hong Kong
Royal Marsden Hospital London UK
Samitivej Hospital Bangkok Thailand
Sheffiled Children Hospital Sheffiled UK
Sir Ganga Ram Hospital New Delhi India
Sloan Kettering Cancer Centre New York USA
University of Malaya Medical Centre Kuala Lumpur Malaysia
QR 8.1.1-1-8 28
 Cordlife Banking Excellence
Cordlife manages100% of all Cordlife companies and operations in Australasian
region with latest technology available to the Indian laboratory – no franchise, no
gimmicks, no foreign collaborators because we are the international direct
promoters
Cordlife group companies are recognised by
AABB, TGA and various government health
authorities.
Cordlife is also the official consultant to the
Singapore government for its public stem cell
bank in 2004 and partner for the Healthcare
blueprint development in Valkenburg, Holland

AABB
India
Singapore Ministry Indonesia Ministry of Health and
ISO TGA of Health Ministry of Health Family Welfare of India

Former Prime Minister of Singapore, His Excellency, Mr Goh Chok Tong,

graced Cordlife India launch at Taj Bengal, 2005
QR 8.1.1-1-8 29
 Cordlife Banking Excellence -WEF
Our 10 years of experience and propriety technology has attained the highest honour of
global recognition by Geneva based WEF - Cordlife service is now available in India

QR 8.1.1-1-8 30
 CordLife India pride our adherence to best international practices.
In addition to AABB standards (America), FACT-Netcord standards (Europe) and
Therapeutic Goods Administration (Australia).
We are now ISO 9001:2008 certified in India, the latest edition of ISO from 2008.

Licensed by the Drug Controller General of India, (DCGI) to process and

store human progenitor cell-cord, CordLife strives for the highest standards
in meeting our vision:

cordlife is to date the only company in India that complies to the

standards set by the American Association of Tissue Banks for umbilical cord
tissue banking.

QR 8.1.1-1-8 31
 Another important question to ask:
What are the Charges?
Cordlife Pricing Plans
Limited period offer:- Storage fee for cord tissues waved for 21 years
Yearly Payment Plan Flexi 24 Flexi 12 Annual
Enrolment 5,000 5,000 5,000
Processing 1,700 x 24 mths 3,150 x 12 mths 37,000
Storage fee* 3,600 3,600 3,600
*(Storage fee payable every year)

18 years One-time payment Flexi 18-24 Flexi 18-12 18 years

Enrolment 5,000 5,000 5,000
Processing & Storage 3,300 x 24 mths 6,100 x12 mths 72,000
Affordable…….
•Various Flexible payment plans available with as low as Rs1,900
•18years + 3 years free from 19th to 21st
•Refer-A-Friend – Get Rs 3,600 when your friend signs up
Committed to help and protect……….
•Free medical concierge in the world- A COMMITMENT
•Free transportation to anywhere in the world- A GUARANTEE

AABB QR8.1.1.12_DCR198
 Cordlife Quality Warranty

Not just about certifications, we hold our quality, our

promise as good as in our contract
“…CordLife shall at its own cost, seek a Cord Blood Unit of a suitable Human Leukocyte
Antigen (“HLA
(“HLA”)”) match to the cord blood donor………..
…If CordLife fails to obtain a Cord Blood Unit of a suitable HLA match, the amount of
damages that you may recover from CordLife shall …be……

…”
* For the Full Clause, please refer to Cord Blood Banking Service Agreement.

The ONLY Cord Blood Bank in India and Asia to offer a

legally binding guarantee as stated in the Agreement for
your child’s precious cord blood

QR 8.1.1-1-8 33
 Question and Answers

QR 8.1.1-1-8 34